Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 13Melanoma 7Neoplasms 3Sarcoma, Kaposi 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia 2Kidney Neoplasms 2Hematologic Neoplasms 2HIV Infections 2Brain Neoplasms 2Acquired Immunodeficiency Syndrome 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Osteosarcoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Margins of Excision 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1

Interventions

Indocyanine Green 2Everolimus 2Sunitinib 1Simvastatin 1Interferon alpha-2 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Margins of Excision × Interferon alpha-2 × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡